CERS
Price
$1.32
Change
-$0.05 (-3.65%)
Updated
Jun 13 closing price
Capitalization
342.62M
46 days until earnings call
IRMD
Price
$58.17
Change
-$1.39 (-2.33%)
Updated
Jun 13 closing price
Capitalization
557.04M
46 days until earnings call
Interact to see
Advertisement

CERS vs IRMD

Header iconCERS vs IRMD Comparison
Open Charts CERS vs IRMDBanner chart's image
Cerus
Price$1.32
Change-$0.05 (-3.65%)
Volume$1.01M
Capitalization342.62M
iRadimed
Price$58.17
Change-$1.39 (-2.33%)
Volume$39.46K
Capitalization557.04M
CERS vs IRMD Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. IRMD commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and IRMD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (CERS: $1.32 vs. IRMD: $58.17)
Brand notoriety: CERS and IRMD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 83% vs. IRMD: 105%
Market capitalization -- CERS: $342.62M vs. IRMD: $557.04M
CERS [@Medical Specialties] is valued at $342.62M. IRMD’s [@Medical Specialties] market capitalization is $557.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileIRMD’s FA Score has 3 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • IRMD’s FA Score: 3 green, 2 red.
According to our system of comparison, IRMD is a better buy in the long-term than CERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while IRMD’s TA Score has 6 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 5 bearish.
  • IRMD’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IRMD is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical Specialties) experienced а -12.58% price change this week, while IRMD (@Medical Specialties) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.80%. For the same industry, the average monthly price growth was +3.14%, and the average quarterly price growth was +0.31%.

Reported Earning Dates

CERS is expected to report earnings on Jul 31, 2025.

IRMD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (-1.80% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IRMD($557M) has a higher market cap than CERS($343M). IRMD YTD gains are higher at: 6.418 vs. CERS (-14.286). IRMD has higher annual earnings (EBITDA): 20.8M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. IRMD (49.8M). IRMD has less debt than CERS: IRMD (2.04M) vs CERS (96M). CERS has higher revenues than IRMD: CERS (156M) vs IRMD (65.6M).
CERSIRMDCERS / IRMD
Capitalization343M557M62%
EBITDA-26.34M20.8M-127%
Gain YTD-14.2866.418-223%
P/E RatioN/A31.84-
Revenue156M65.6M238%
Total Cash65.9M49.8M132%
Total Debt96M2.04M4,699%
FUNDAMENTALS RATINGS
CERS vs IRMD: Fundamental Ratings
CERS
IRMD
OUTLOOK RATING
1..100
8824
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
16
Undervalued
PROFIT vs RISK RATING
1..100
10026
SMR RATING
1..100
9440
PRICE GROWTH RATING
1..100
6243
P/E GROWTH RATING
1..100
10028
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRMD's Valuation (16) in the Medical Specialties industry is in the same range as CERS (44). This means that IRMD’s stock grew similarly to CERS’s over the last 12 months.

IRMD's Profit vs Risk Rating (26) in the Medical Specialties industry is significantly better than the same rating for CERS (100). This means that IRMD’s stock grew significantly faster than CERS’s over the last 12 months.

IRMD's SMR Rating (40) in the Medical Specialties industry is somewhat better than the same rating for CERS (94). This means that IRMD’s stock grew somewhat faster than CERS’s over the last 12 months.

IRMD's Price Growth Rating (43) in the Medical Specialties industry is in the same range as CERS (62). This means that IRMD’s stock grew similarly to CERS’s over the last 12 months.

IRMD's P/E Growth Rating (28) in the Medical Specialties industry is significantly better than the same rating for CERS (100). This means that IRMD’s stock grew significantly faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSIRMD
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
60%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 7 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
58%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
61%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DHLSX29.05-0.19
-0.65%
Diamond Hill Long-Short I
PJFAX61.15-0.87
-1.40%
PGIM Jennison Growth A
CCPIX45.38-0.72
-1.56%
Calvert Mid-Cap I
FAFSX35.24-0.81
-2.25%
Fidelity Advisor Financials M
RYCVX158.60-5.95
-3.62%
Rydex Dow 2x Strategy H

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-3.65%
LAB - CERS
52%
Loosely correlated
N/A
NNOX - CERS
47%
Loosely correlated
-2.33%
SGHT - CERS
46%
Loosely correlated
-1.90%
BFLY - CERS
46%
Loosely correlated
-5.74%
ICUI - CERS
45%
Loosely correlated
-0.26%
More

IRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, IRMD has been loosely correlated with HBIO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IRMD jumps, then HBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRMD
1D Price
Change %
IRMD100%
-2.33%
HBIO - IRMD
54%
Loosely correlated
-2.79%
ITGR - IRMD
44%
Loosely correlated
-0.38%
VREX - IRMD
44%
Loosely correlated
-3.99%
ICUI - IRMD
44%
Loosely correlated
-0.26%
CERS - IRMD
43%
Loosely correlated
-3.65%
More